The middle-arm fistula as a valuable surgical approach in patients with end-stage renal disease  by Bonforte, Giuseppe et al.
The middle-arm fistula as a valuable surgical
approach in patients with end-stage renal disease
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Background: American and European guidelines recommend the distal radial-cephalic fistula (dRCF) as the first and best
hemodialysis access in patients with end-stage renal disease (ESRD). However, this kind of arteriovenous fistula (AVF)
shows a limited primary unassisted patency and frequently needs surgical revisions or angiographic procedures, or both.
When dRCF is not feasible, guidelines suggest a proximal brachiocephalic AVF. The middle-arm fistula (MAF), or
autogenous forearm radial-median direct access, has been suggested as a possible alternative approach. This study
evaluated MAF primary unassisted patency, the most frequent causes of MAF failure, and the possible related factors.
Methods: Data on patients with a MAF placed from January 1991 until June 2008 were retrospectively collected. The
probability of MAF failure overall and by the main subgroups was estimated according to Kaplan-Meier with Greenwood
standard error (SE). Comparison of failure among different subgroups was performed using the log rank test in
univariate analyses. The Cox regression model was used to investigate factors that independently affected the overall
hazard of failure and cause-specific hazard of thrombosis.
Results: At the end of follow-up, 14.0% of MAF failed (11.6% thrombosis, 1.7% stenosis, 0.7% failed maturation), and
44.2% of MAF were still working. Cumulative probability of MAF unassisted primary patency after 4 years from the
creation was 79%. Univariate analyses highlighted that women (P  .019), underweight patients (P  .010), and MAF
implantation after starting hemodialysis (P< .001) had a higher risk of MAF failure for any cause than men, normal and
overweight patients, andMAF implanted before starting hemodialysis. Results of the Coxmultivariate analysis for overall
MAF failure confirmed that only MAF implantation before starting hemodialysis is a protective factor against any failure
(P .003), whereas female gender (P .016) was associated with an increase of the thrombosis hazard ratio to 2.04 (95%
confidence interval, 1.14-3.63).
Conclusion: Our data demonstrate that MAF has a good unassisted primary patency and suggest that this kind of AVF
could be a valuable alternative surgical approach when dRCF is not feasible in ESRD patients. ( J Vasc Surg 2010;52:
1551-6.)American and European guidelines recommend the
distal wrist radial-cephalic fistula (dRCF), proposed by
Cimino-Brescia,1 as the first and best hemodialysis ac-
cess.2-4 This arteriovenous fistula (AVF) requires an easy
placement procedure that allows preservation of the pa-
tient’s vascular network and needs fewer interventions for
complications (infection, stenosis and thrombosis) com-
pared with grafts and central venous catheters.5-7
When dRCF is not feasible, guidelines suggest a direct
or transposed brachial artery inflow AVF placement in
the elbow region or in the upper arm.2-4 These second
options, compared with a dRCF, enable an higher flow
AVF, with a shorter maturation time and an earlier
development of more easily available veins for hemodi-
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doi:10.1016/j.jvs.2010.06.165alysis.8 However, the surgical intervention required for
the brachial artery inflow AVF placement has a greater
risk of distal steal syndrome, arm ischemia, and high-
output heart failure9 than the distal approach. To avoid
these complications, a smaller-sized anastomosis must be
performed in relationship to the size of the brachial
artery to limit the flow through the fistula.
In the last 30 years, the hemodialysis population has
become older and sicker, comorbid factors have increased,
and the life expectancy has been reduced,10 so nowadays it
is even more important to create a working vascular access
with as few complications as possible. Several studies have
shown the classic dRCF has an increased rate of early failure
(early thrombosis or failed maturation) and a limited pri-
mary unassisted patency due to the frequent need of surgi-
cal revisions or angiographic procedures, or both, with
increased costs and reduced patient quality of life.11,12
For these reasons, it is correct to wonder if the dRCF
still represents the first best choice for vascular access. The
middle-arm fistula (MAF), where the anastomosis is be-
tween proximal radial artery and the nearest suitable vein
located in the antecubital fossa (median, perforating, or
cephalic vein), is suggested as an alternative option. This
was a retrospective study that used prospective hospital
registries containing nearly 20 years of data on the Italian
experience with MAF. The aim of the study was to evaluate
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of MAF failure, and the possible related factors.
METHODS
Patients. Data on patients with a MAF placed from
January 1991 until June 2008 were retrospectively col-
lected. Four dialysis centers of Northern Italy contributed
to the data collection.
All patients with a MAF were included, and 459 access
procedures were registered. MAF placement was per-
formed as an outpatient procedure, as previously de-
scribed.13 Patients underwent a thorough anamnestic and
physical examination, including upper arm inspection for
asymmetry of pulse and blood pressure, an Allen test, and
assessment of superficial vein patency during venous out-
flow restriction with a tourniquet. Two or more comorbid
factors among diabetes mellitus, atherosclerosis, obesity,
neoplasm, coagulation disease, and peritoneal dialysis fail-
ure, or age 65 years determined assignment of MAF as
the first-choice vascular access.
According to recommended standards,14 MAF was
defined as an autogenous forearm radial-median direct
access.
Gender and body mass index of patients, age at MAF
implantation, timing of MAF implantation (before or after
the start of hemodialysis), and information about MAF
implantation as the first or second choice were collected.
Study end points and definitions. The end point was
the loss of primary access patency. Time free from primary
intervention was defined as the time from placement to any
type of first intervention, including surgical revision, angio-
plasty, switching to a central venous catheter, or creation of
a new access. The creation of a new fistula on the contralat-
eral arm was considered a new vascular access. A fistula was
defined as functional when it was possible to use it for
hemodialysis with two needles and had a blood flow of at
350 mL/min, without access recirculation, to maintain a
treatment time of 4 hours during 6 hemodialysis ses-
sions in 1 month. Dialysis adequacy was monitored by
regular measurement of Kt/V (K, dialyzer clearance of
urea; t, dialysis time; and V, patient’s total body water)
according to Daugirdas.15
Early MAF failure was defined as thrombosis30 days
from implantation, applying an intent-to-treat rule. Failed
maturation was defined as a MAF that was not suitable for
dialysis use 60 days. Data were also analyzed to identify
more frequent causes of failure and possible related factors.
Operative method. The MAF surgical method has
been previously described.13 Briefly, after proper preoper-
ative antibiotic prophylaxis and under local anesthesia, a 2-
to 3-cm incision along the fold between the brachioradialis
muscle and the pronator teres was made, starting 3 cm
below the crease of the elbow, running medially. The
nearest vein (median, perforating, or cephalic) to the radial
artery was isolated, and the antebrachial aponeurosis was
exposed and incised. The radial artery was isolated and
mobilized together with its vasculonervous plexus. After a
longitudinal medial venotomy, the vein was irrigated andthe first valve was ruptured to allow retrograde flow. Then,
the longitudinal medial arteriotomy was performed. The
anastomosis was placed according to the Tellis technique
(Fig 1). The operation was completed with subcutaneous
fat suture in layers and intradermal suture of the skin.
Statistical analysis. Patient characteristics were de-
scribed by median and interquartile range for continuous
variables and by frequencies and percentages for qualitative
variables. The probability of MAF failure overall and by the
main subgroups was estimated according to Kaplan-Meier
with Greenwood standard error (SE), and comparison of
failure between different subgroups was performed using
the log rank test in univariate analyses.
Observation time was censored on June 2008 if the pa-
tientwas alivewith aworkingMAF at the latest follow-up and
was censored before June 2008 for 162 patients who died,
11 who underwent transplantation, 18 who transferred to
another hospital with a working MAF, and 1 patient whose
fistula was closed for a nonclinical reason. Four patients
were lost to follow-up, alive with working MAF, 2 years
before the end of the study. A value of P .05 was consid-
ered significant.
The multivariate Cox regression model was used to
investigate factors that independently affected the overall
hazard of failure and cause-specific hazard of thrombosis.
By definition of cause-specific hazard, considered events
were only thromboses, and patients at risk were those alive
with a working MAF and under observation. The Cox
model was run on all the recruited patients considering the
variables: gender, age of patient at MAF implantation
(60, 60-70, 70-80, 80 years), BMI (kg/m2) classified
as underweight (BMI  18.5), normal weight (BMI 18.5-
25), and overweight (BMI25), causes of end-stage renal
disease (ESRD), MAF creation after or before the starting
hemodialysis, and MAF as the first or second choice access,
as reported in Table I.
The assumption of proportional hazards was assessed
by means of graphic checks on the log cumulative hazard
for each covariate, and all the considered variables satisfied
the assumption.
Results of the Cox model are expressed in terms of
estimated hazard ratios (HRs) and 95% confidence intervals
(95% CIs). SAS 9.1 software (SAS Institute, Cary, NC) was
Fig 1. Autogenous forearm radial-median direct-access middle-
arm fistula with a bidirectional flow.used for all computations.
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The clinical and demographic characteristics of the 459
patients at MAF implantation are described in Table II.
Most were men (59.9%), the median age at the recruitment
was 71.4 years (Fig 2), and the median BMI was 23.9
kg/m2. In 80% of patients the MAF was the primary
vascular access, and 51% were placed after the hemodialysis
Table I. Multivariate Cox regression model on 459 patien
middle-arm fistula (MAF) failure (model I) and on cause-s
Risk factors
Model I
HR (95% CI)
Gender
Male Reference
Female 1.65 (0.99-2.77)
Age at MAF creation
60 Reference
60-70 1.46 (0.67-3.21)
70-80 1.09 (0.49-2.41)
80 1.21 (0.51-2.85)
BMI, kg/m2
Underweight Reference
Normal 0.57 (0.26-1.26)
Overweight 0.41 (0.17-0.98)
Cause of renal failure
Glomerulonephritis Reference
Ischemic nephropathy 2.42 (1.09-5.39)
Diabetes 1.65 (0.70-3.93)
Other 2.07 (0.99-4.32)
MAF before HD starting
No Reference
Yes 0.41 (0.23-0.73)
MAF as first choice
No Reference
Yes 0.90 (0.48-1.68)
BMI, Body mass index; CI, confidence interval; HD, hemodialysis; HR, ha
Table II. Demographic and clinical characteristics of
patients at recruitment
Variable No. (%) or median (IQR)
Patients, No. 459
Characteristics
Male 275 (59.9)
Age at MAF, year 71.4 (63.9-78.2)
Body mass index, kg/m2 23.9 (21.4-26.6)
Cause of renal failure
Ischemic nephropathy 115 (25.1)
Diabetes mellitus 105 (22.9)
Glomerulonephritis 100 (21.8)
ADPKD 24 (5.2)
Systemic disease involving kidney 19 (4.1)
Unknown etiology 32 (7.0)
Other cause 64 (13.9)
MAF implantation
After start of hemodialysis 232 (50.5)
As first choice 369 (80.4)
ADPKD, Autosomal dominant polycystic kidney disease; IQR, interquartile
range; MAF, middle-arm fistula.had started. The main causes of renal failure were ischemicnephropathy (25.1%), diabetes mellitus (22.9%), and glo-
merulonephritis (21.8%).
At the end of follow-up, 14.0% of MAF failed be-
cause of thrombosis (11.6%), stenosis (1.7%), and failed
maturation (0.7%); whereas 44.2% of MAF were still
working with patients alive (Table III). The median
follow-up time was 1.9 years. The probability of MAF
unassisted primary patency after 4 years from the implan-
tation was about 79% (Fig 3). The probability of MAF
failure was mainly due to thrombosis, with a cumulative
incidence at the same time of about 17%. The probability
of early failure was about 3.5%.
Univariate analyses (Table IV) highlighted that women
(P  .019), underweight patients (P  .010), and MAF
implantation after starting hemodialysis (P .001, Fig 4) had
a higher risk of MAF failure for any cause than men, normal
and overweight patients, and MAF implanted before hemo-
dialysis started. No significant differences were observed for
patient age at MAF implantation, cause of renal failure, and
MAF implantation as the first or second choice.
Results of the Coxmultivariate analysis for overall MAF
failure confirmed that MAF implantation before the start of
hemodialysis was a protective factor against failure (P 
.003; Table I). The 4-year unassisted primary patency
probability in patients with a MAF placed before starting
hemodialysis was 87.6% (95% CI, 82.1%-93.4%), whereas
in patients with the MAF implanted after hemodialysis
started, the 4-year unassisted primary patency probability
was 72.4% (95% CI, 63.4%-82.6%), other characteristics
aluating the impact of prognostic factors on overall
c hazard of thrombosis (model II)
Model II
P HR (95% CI) P
Reference
.055 2.04 (1.14-3.63) .016
Reference
.743 1.65 (0.68-3.98) .663
1.19 (0.49-2.92)
1.42 (0.56-3.62)
Reference
.140 0.50 (0.22-1.15) .100
0.35 (0.14-0.88)
Reference
1.94 (0.82-4.60)
.120 1.35 (0.52-3.52) .325
1.88 (0.87-4.08)
Reference
.003 0.37 (0.20-0.70) .002
Reference
.741 1.06 (0.53-2.13) .876
tio.ts ev
pecifibeing equal.
dle-ar
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showed that also male gender (P  .016), in addition to
MAF creation before starting hemodialysis (P .002), was
associated with a decrease of the MAF failure hazard due to
thrombosis; in particular, women had a 2.04-fold increase
(95% CI, 1.14-3.63) in the risk of thrombosis compared
with men (Table I).
In summary, the analysis on the overall causes of MAF
failure indicated that a woman with MAF implanted after
starting hemodialysis had an expected MAF unassisted
primary patency of about 43.3% (95% CI, 23.0%-81.8%),
whereas a man with MAF placed before starting hemodial-
ysis had an expected MAF unassisted primary patency of
82.2% (95% CI, 73.5%-92.0%).
DISCUSSION
Our data provide some new information on options for
hemodialysis access. The MAF unassisted primary patency
rates were 92.4% at 1 year and 79.3% at 4 years, with a 3.5%
Fig 2. Age distribution at mid
Table III. Distribution of middle-arm fistula (MAF)
status at the end of follow-up
Outcome No. (%)
Patient status
Alive with working MAFa 203 (44.2)
Died with working MAF 162 (35.3)
Transplant with working MAF 11 (1.4)
Transferred with working MAF 18 (8.9)
MAF removal for nonclinical reason 1 (1.2)
Early thrombosis 14 (4.1)
Late thrombosis 39 (9.5)
Stenosis 8 (8.7)
Failed MAF maturation 60 days 3 (3.7)
Total 459 (100)
aFour patients were lost to follow-up 2 years before the end of the study.probability of early failure.MAFwas the first-choice AVF in80% of patients. Our study proved MAF had excellent
unassisted primary patency. In fact, MAF survival at 1 year
in our population was higher than survival reported in
recent literature reviews and meta-analyses.11,16,17 More-
over, early MAF failure in our patients was less (3.5%) than
that described in other case series. In studies in the 1980s,
the early AVF failure was 10% to 20%, whereas failures in
more recent series are two to five times higher.11 Only
Konner18 reported an early failure of 2% in a study where
MAF was the first-choice vascular access in about 50% of
patients. However, these studies11,16,17 had some limita-
tions: MAF was not considered as the first-choice vascular
access, and the mean follow-up period was 12 months,
which was relatively short.16Moreover all published studies
reported AVF unassisted primary patency and its related
factors considering together distal and proximal vascular
access. To our knowledge, our study is the first that ana-
lyzes factors influencing specifically MAF unassisted pri-
m fistula (MAF) implantation.
Fig 3. Patency probability of 459 implanted middle-arm fistulas
(MAFs, solid line) is shown with the 95% confidence intervals
(dashed lines). SE, Standard error.mary patency.
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starting hemodialysis) was the only independent factor
affecting MAF survival. Our data show that MAF implan-
tation before starting hemodialysis has a pivotal role in the
long-term access patency: timing of MAF creation was the
main factor influencing the overall MAF survival. Previ-
ously, Weber et al19 showed similar data. In their study, the
probability of complication-free survival at 12 months was
62% in the AVF group (46% dRCF, 54% upper arm fistula)
created before starting hemodialysis, with a low incidence
Table IV. Probability of middle-arm fistula (MAF) patenc
459 hemodialysis (HD) patients (64 obstructions)
Characteristics
(n  459) No. (%)
Cu
2-month
Gender
Male 275 (59.9) 97.4 (1.0)
Female 184 (40.1) 90.7 (2.2)
Age at MAF, year
60 82 (17.8) 97.5 (1.8)
60-70 128 (27.9) 92.9 (2.3)
70-80 162 (35.3) 94.9 (1.8)
80 87 (19.0) 94.1 (2.6)
BMI, kg/m2
Underweight 35 (7.6) 85.5 (6.0)
Normal 247 (53.8) 95.5 (1.3)
Overweight 177 (38.6) 95.5 (1.6)
Cause of renal failure
Ischemic nephropathy 115 (25.1) 94.7 (2.1)
Diabetes 105 (22.9) 94.2 (2.3)
Glomerulonephritis 100 (21.8) 97.0 (1.7)
Other cause 139 (30.2) 93.4 (2.1)
MAF after starting HD
Yes 232 (50.5) 92.1 (1.8)
No 227 (49.5) 97.3 (1.1)
MAF as first choice
Yes 369 (80.4) 94.8 (1.2)
No 90 (19.6) 94.4 (2.4)
BMI, Body mass index; SE, standard error.
Fig 4. Patency probability by timing of middle-arm fistula (MAF)
implantation (solid lines,) before or after the start of hemodialysis
(HD) is shown with the 95% confidence intervals (dashed lines).of thrombotic events. Moreover, our data do not provideevidence of a cause-and-effect connection between the
timing of MAF construction and longer access survival.
People in the Weber et al study19 with a high burden of
cardiovascular disease were at high risk for early fistula
failure. We also found similar data: patients with ischemic
renal disease showed a trend of increased risk of fistula
failure compared with patients affected by glomerulone-
phritis renal disease.
The cause-specific analysis showed that MAF creation
after starting hemodialysis and female gender were the only
factors statistically associated with thrombosis. The latter
data were expected because it is well known that the vascu-
lar network in women is characterized by smaller vessel
diameter compared with men.
MAF survival in our population was not significantly
influenced by age. In fact, even though the median age of
our population was70 years, this was not associated with
a higher incidence rate of events, as has been recently
reported.20,21
Although good MAF survival results have been repor-
ted18,21,22 and MAF has been used since the end of the
1970s,22,23 this kind of AVF had a slow diffusion over the
years. Created as a second choice after dRCF to reduce the risk
of distal ischemia, MAF has a more challenging surgical ap-
proach compared with a wrist or brachial artery inflow AVF
because of the discrepancy between the radial artery tract
used as inflow and the superficial veins (median or ce-
phalic).
Looking at our results, we wonder why we observed
demographic and clinical characteristics at recruitment of
tive probability of patency, mean (SE)
P
(log rank)1-year 2-year 4-year
6.2 (1.2) 89.8 (2.3) 80.4 (4.1) .019
6.9 (2.6) 82.3 (3.1) 77.2 (4.1)
4.8 (2.5) 91.4 (3.4) 83.4 (6.6) .694
1.0 (2.6) 84.6 (3.7) 82.1 (4.3)
2.6 (2.2) 88.2 (3.0) 77.5 (5.1)
1.6 (3.1) 80.9 (5.4) 78.5 (5.0)
8.8 (7.2) 69.4 (8.9) 69.4 (8.9) .010
2.5 (1.8) 87.5 (2.5) 73.5 (4.8)
4.9 (1.8) 89.1 (2.8) 89.1 (2.8)
9.3 (3.1) 79.9 (4.6) 77.3 (5.2) .142
4.2 (2.3) 88.0 (3.7) 88.0 (3.7)
5.9 (2.0) 95.9 (2.0) 84.3 (5.8)
1.0 (2.5) 84.5 (3.7) 73.0 (5.9)
0.0 (2.0) 82.2 (3.1) 68.9 (5.2) .001
4.8 (1.5) 90.9 (2.2) 87.7 (3.0)
2.9 (1.4) 87.0 (2.1) 81.0 (3.1) .220
0.4 (3.3) 86.0 (4.3) 72.5 (7.5)y by
mula
9
8
9
9
9
9
7
9
9
8
9
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9higher MAF patency compared with rates in published
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was the first-choice fistula in 80% of patients. We think our
study could encourage reconsideration of the current rec-
ommendations in clinical practice guidelines in an elderly
population with ischemic and diabetic nephropathy as the
main causes of ESRD, although the RCF remains the first
vascular access choice in properly selected patients.24 MAF
could be proposed as the first-choice AVF in selected
patients when a dRCF is not feasible and as a second step in
case of dRCF failure in all patients before attempting to
place a brachial artery inflow AVF.
Our work has some limitations. First, because our aim
was to evaluate MAF survival, focusing on this vascular
access placed in selected patients, we did not require AVF
data in patients who did not undergo MAF operations.
Second, we were able to collect only Northern Italy MAF
data, thus giving a partial overview on the Italian MAF
experience overall.
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